Results 51 to 60 of about 180,701 (284)

Drivers of MERS-CoV transmission: what do we know? [PDF]

, 2016
This article is made available for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source.
Al-Tawfiq, Jaffar A., Memish, Ziad A.
core   +1 more source

Measures for diagnosing and treating infections by a novel coronavirus responsible for a pneumonia outbreak originating in Wuhan, China. [PDF]

, 2020
On 10 January 2020, a new coronavirus causing a pneumonia outbreak in Wuhan City in central China was denoted as 2019-nCoV by the World Health Organization (WHO).
Du, Lanying, Jiang, Shibo, Ojcius, David M, Pan, Chungen, Yu, Fei   +4 more
core   +1 more source

SARS-CoV-2 antibodies persist

Science, 2020
Coronavirus As the number of daily COVID-19 cases continues to mount worldwide, the nature of the humoral immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains uncertain. Wajnberg et al. used a cohort of more than 30,000 infected individuals with mild to moderate COVID-19 symptoms to determine the robustness and ...
openaire   +1 more source

Potent neutralization of SARS-CoV-2 variants of concern by an antibody with an uncommon genetic signature and structural mode of spike recognition

Cell Reports, 2021
Summary: The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) lineages that are more transmissible and resistant to currently approved antibody therapies poses a considerable challenge to the clinical treatment of coronavirus ...
Kevin J. Kramer, Nicole V. Johnson, Andrea R. Shiakolas, Naveenchandra Suryadevara, Sivakumar Periasamy, Nagarajan Raju, Jazmean K. Williams, Daniel Wrapp, Seth J. Zost, Lauren M. Walker, Steven C. Wall, Clinton M. Holt, Ching-Lin Hsieh, Rachel E. Sutton, Ariana Paulo, Rachel S. Nargi, Edgar Davidson, Benjamin J. Doranz, James E. Crowe, Jr., Alexander Bukreyev, Robert H. Carnahan, Jason S. McLellan, Ivelin S. Georgiev   +22 more
doaj   +1 more source

SARS-CoV-2-Neutralizing Antibodies

Vaccines
The COVID-19 pandemic, triggered by the SARS-CoV-2 virus, has profoundly and permanently affected many aspects of the world [...]
Yawen Liu, Jianhui Nie
openaire   +3 more sources

Dromedary camels as a natural source of neutralizing nanobodies against SARS-CoV-2

JCI Insight, 2021
The development of prophylactic and therapeutic agents for coronavirus disease 2019 (COVID-19) is a current global health priority. Here, we investigated the presence of cross-neutralizing antibodies against severe acute respiratory syndrome coronavirus ...
Lotfi Chouchane, Jean-Charles Grivel, Elmoubasher Abu Baker Abd Farag, Igor Pavlovski, Selma Maacha, Abbirami Sathappan, Hamad Eid Al-Romaihi, Sirin W.J. Abuaqel, Manar Mahmoud Ahmad Ata, Aouatef Ismail Chouchane, Sami Remadi, Najeeb Halabi, Arash Rafii, Mohammed H. Al-Thani, Nico Marr, Murugan Subramanian, Jingxuan Shan   +16 more
doaj   +1 more source

First Description of Serological Evidence for SARS-CoV-2 in Lactating Cows

Animals, 2022
Following the COVID-19 epidemic outbreak in Ariano Irpino, Campania region (Italy), we tested lactating cows for the presence of SARS-CoV-2 on a cattle farm at which, prior to the investigation, 13 of the 20 farmworkers showed COVID-19-like symptoms, and
Filomena Fiorito, Valentina Iovane, Ugo Pagnini, Claudia Cerracchio, Sergio Brandi, Martina Levante, Luisa Marati, Gianmarco Ferrara, Virginio Tammaro, Esterina De Carlo, Giuseppe Iovane, Giovanna Fusco   +11 more
doaj   +1 more source

Update on therapeutic options for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) [PDF]

, 2016
This article is made available for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source.
Al-Tawfiq, Jaffar A., Memish, Ziad A.
core   +1 more source

Monoclonal antibodies lock down SARS-CoV-2 spike

Trends in Immunology, 2023
SARS-CoV-2 rapidly accumulated mutations in its immunodominant receptor-binding domain (RBD), rendering all clinically authorized monoclonal antibodies (mAbs) ineffective. Liu et al. unveil potent human mAbs that neutralize all tested SARS-CoV-2 variants by locking the Spike protein RBD in a downward conformation, thus inhibiting receptor engagement.
Huang, Hsiang-Chi, Angeletti, Davide
openaire   +2 more sources

Detection of breastmilk antibodies targeting SARS-CoV-2 nucleocapsid, spike and receptor-binding-domain antigens

Emerging Microbes and Infections, 2020
A 40-year-old female was found to have strongly neutralizing SARS-CoV-2 breastmilk IgA and IgG antibodies reactive against multiple SARS-CoV-2 antigens at 2.5 months after documented infection with SARS-CoV-2.
D. M. Favara, M. L. Ceron-Gutierrez, G. W. Carnell, J. L. Heeney, P. Corrie, R. Doffinger   +5 more
doaj   +1 more source